Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free CLVR Stock Alerts

Clever Leaves (CLVR) Competitors

Clever Leaves logo
Compare

CLVR vs. CARM, CMRA, CALA, EFTR, and EVLO

Should you buy Clever Leaves stock or one of its competitors? MarketBeat compares Clever Leaves with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clever Leaves include Carisma Therapeutics (CARM), Comera Life Sciences (CMRA), Calithera Biosciences (CALA), eFFECTOR Therapeutics (EFTR), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry.

How does Clever Leaves compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Carisma Therapeutics Neutral
Clever Leaves Neutral

Carisma Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 4212.86, meaning that its share price is 421,186% more volatile than the broader market.

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Clever Leaves has higher revenue and earnings than Carisma Therapeutics. Clever Leaves is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

Carisma Therapeutics currently has a consensus price target of $1.00, suggesting a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Clever Leaves.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carisma Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
Clever Leaves
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Clever Leaves has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company Net Margins Return on Equity Return on Assets
Carisma Therapeutics-254.28% N/A -192.17%
Clever Leaves N/A N/A N/A

Summary

Carisma Therapeutics beats Clever Leaves on 7 of the 13 factors compared between the two stocks.

How does Clever Leaves compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Clever Leaves has higher revenue and earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Clever Leaves N/A N/A N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Clever Leaves Neutral

Comera Life Sciences has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 4212.86, suggesting that its share price is 421,186% more volatile than the broader market.

6.9% of Clever Leaves shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by company insiders. Comparatively, 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Clever Leaves beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Clever Leaves compare to Calithera Biosciences?

Clever Leaves (NASDAQ:CLVR) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Clever Leaves has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Calithera Biosciences Neutral

Clever Leaves has a beta of 4212.86, indicating that its share price is 421,186% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.05, indicating that its share price is 205% less volatile than the broader market.

Summary

Clever Leaves beats Calithera Biosciences on 6 of the 6 factors compared between the two stocks.

How does Clever Leaves compare to eFFECTOR Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Clever Leaves N/A N/A N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Clever Leaves Neutral

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Comparatively, 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Clever Leaves has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

eFFECTOR Therapeutics has a beta of 2.41, meaning that its stock price is 141% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 4212.86, meaning that its stock price is 421,186% more volatile than the broader market.

Summary

Clever Leaves beats eFFECTOR Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Clever Leaves compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Clever Leaves N/A N/A N/A

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Clever Leaves Neutral

Clever Leaves has higher revenue and earnings than Evelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

Evelo Biosciences has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 4212.86, indicating that its share price is 421,186% more volatile than the broader market.

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by company insiders. Comparatively, 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Clever Leaves beats Evelo Biosciences on 5 of the 7 factors compared between the two stocks.

Get Clever Leaves News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLVR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

CLVR vs. The Competition

Export
MetricClever LeavesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E Ratio0.001.4620.9925.66
Price / SalesN/A119.63560.3086.31
Price / CashN/A20.0743.4956.67
Price / BookN/A7.5910.417.14
Net Income-$17.90M-$3.64M$3.57B$335.98M

Clever Leaves Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLVR
Clever Leaves
N/AN/AN/AN/A$1K$17.42MN/A560
CARM
Carisma Therapeutics
2.3139 of 5 stars		$0.00
flat		$1.00
+999,900.0%		-99.9%$4K$10.77M0.0020
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
CALA
Calithera Biosciences
N/A$0.00
flat		N/A-66.7%$2KN/AN/A60
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/A-75.0%$2KN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CLVR) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel